Mesenchymal stem cells (MSCs) are attractive candidates for novel cell-therapy applications. However, the in vitro expansion of MSCs typically depends on the presence of fetal bovine serum (FBS) and coating materials derived from animal sources, which may cause contamination in clinical applications. In this study, we investigated whether human umbilical cord extract (UCE) could serve as a serum replacement and whether collagen purified from umbilical cord (UC-collagen) could act as an extracellular matrix (ECM) for the in vitro culture of MSCs derived from human UC (UC-MSCs). A total of 5.61±0.54 mg UCE and 18.41±2.42 mg collagen were extracted, and 1.3±0.2×105 cells were isolated from 1 g of UC, as determined by the expression of typical MSC surface markers. Importantly, the proliferation and stemness of the UC-MSCs cultured with the UCE media were similar to those cultured under FBS conditions on UC-collagen-treated plates for eight passages. Based on these results, we suggest that UCs, which are discarded as medical waste, represent a viable alternative source of xeno-free biomaterials to replace animal-derived serum and ECM materials for the cultivation of various cell types, including UC-MSCs, adipose tissue-derived MSCs, bone marrow-derived MSCs, and fibroblasts. This innovative xeno-free MSCs culture system can overcome many of the problems associated with immunogenicity, and it will further contribute to the enhancement of treatment efficiency.
Get full access to this article
View all access options for this article.
References
1.
LiuY, BerendsenAD, JiaS, LotinunS, BaronR, FerraraN, OlsenBR. 2012. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest, 122:3101–3113.
2.
WangX, LiaoS, NelsonER, SchmalzigaugR, SpurneyRF, GuilakF, PremontRT, Gesty-PalmerD. 2012. The cytoskeletal regulatory scaffold protein GIT2 modulates mesenchymal stem cell differentiation and osteoblastogenesis. Biochem Biophys Res Commun, 425:407–412.
3.
RochaB, CalamiaV, MateosJ, Fernandez-PuenteP, BlancoFJ, Ruiz-RomeroC. 2012. Metabolic labeling of human bone marrow mesenchymal stem cells for the quantitative analysis of their chondrogenic differentiation. J Proteome Res, 11:5350–5361.
4.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS, GianniAM. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
5.
KodeJA, MukherjeeS, JoglekarMV, HardikarAA. 2009. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy, 11:377–391.
6.
KitazawaY, LiXK, XieL, ZhuP, KimuraH, TakaharaS. 2012. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats. Cell Transplant, 21:581–590.
7.
SolchagaLA, ZaleEA. 2012. Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am J Stem Cells, 1:138–145.
8.
FrankeH, GallaH, BeuckmannCT. 2000. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc, 5:248–256.
9.
NagaiM, HayakawaT, FukatsuA, YamamotoM, FukumotoM, NagahamaF, MishimaH, YoshinariM, NemotoK, KatoT. 2002. In vitro study of collagen coating of titanium implants for initial cell attachment. Dent Mater J, 21:250–260.
10.
NakamizoA, MariniF, AmanoT, KhanA, StudenyM, GuminJ, ChenJ, HentschelS, VecilGet al.2005. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res, 65:3307–3318.
11.
StenderupK, JustesenJ, ClausenC, KassemM. 2003. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone, 33:919–926.
12.
LyahyaiJ, MedianoDR, RaneraB, SanzA, RemachaAR, BoleaR, ZaragozaP, RodellarC, Martin-BurrielI. 2012. Isolation and characterization of ovine mesenchymal stem cells derived from peripheral blood. BMC Vet Res, 8:169.
13.
HuangYC, ParoliniO, La RoccaG, DengL. 2012. Umbilical cord versus bone marrow-derived mesenchymal stromal cells. Stem Cells Dev, 21:2900–2903.
14.
KadamS, GovindasamyV, BhondeR. 2012. Generation of functional islets from human umbilical cord and placenta derived mesenchymal stem cells. Methods Mol Biol, 879:291–313.
15.
BaiJ, HuY, WangYR, LiuLF, ChenJ, SuSP, WangY. 2012. Comparison of human amniotic fluid-derived and umbilical cord Wharton's jelly-derived mesenchymal stromal cells: characterization and myocardial differentiation capacity. J Geriatr Cardiol, 9:166–171.
16.
WeiH, TanG, QiuMS, KongG, YongP, KohC, OoiTH, LimSY, WongP, GanSU, ShimW. 2012. One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells. Stem Cell Res, 9:87–100.
17.
FanCG, ZhangQJ, ZhouJR. 2011. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev, 7:195–207.
18.
VolarevicV, ArsenijevicN, LukicML, StojkovicM. 2011. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells, 29:5–10.
19.
SelvaggiTA, WalkerRE, FleisherTA. 1997. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood, 89:776–779.
20.
HudsonJE, MillsRJ, FrithJE, BrookeG, Jaramillo-FerradaP, WolvetangEJ, Cooper-WhiteJJ. 2011. A defined medium and substrate for expansion of human mesenchymal stromal cell progenitors that enriches for osteo- and chondrogenic precursors. Stem Cells Dev, 20:77–87.
WangHS, HungSC, PengST, HuangCC, WeiHM, GuoYJ, FuYS, LaiMC, ChenCC. 2004. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22:1330–1337.
23.
SchugarRC, ChirieleisonSM, WescoeKE, SchmidtBT, AskewY, NanceJJ, EvronJM, PeaultB, DeasyBM. 2009. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol, 2009:789526.
24.
GauthamanK, YeeFC, CheyyatraivendranS, BiswasA, ChoolaniM, BongsoA. 2012. Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem, 113:2027–2039.
25.
FongCY, GauthamanK, CheyyatraivendranS, LinHD, BiswasA, BongsoA. 2012. Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. J Cell Biochem, 113:658–668.
26.
ChaseLG, YangS, ZacharV, YangZ, LakshmipathyU, BradfordJ, BoucherSE, VemuriMC. 2012. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med, 1:750–758.
27.
SimoesIN, BouraJS, Dos SantosF, AndradePZ, CardosoCM, GimbleJM, da SilvaCL, CabralJM. 2013. Human mesenchymal stem cells from the umbilical cord matrix: successful isolation and ex vivo expansion using serum-/xeno-free culture media. Biotechnol J, 8:448–458.
28.
MitchellKE, WeissML, MitchellBM, MartinP, DavisD, MoralesL, HelwigB, BeerenstrauchM, Abou-EasaKet al.2003. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells, 21:50–60.
29.
MalkowskiA, SobolewskiK, JaworskiS, BankowskiE. 2007. FGF binding by extracellular matrix components of Wharton's jelly. Acta Biochim Pol, 54:357–363.
30.
MalkowskiA, SobolewskiK, JaworskiS, BankowskiE. 2008. TGF-beta binding in human Wharton's jelly. Mol Cell Biochem, 311:137–143.
31.
SobolewskiK, BankowskiE, ChyczewskiL, JaworskiS. 1997. Collagen and glycosaminoglycans of Wharton's jelly. Biol Neonate, 71:11–21.
32.
MeyerFA, Laver-RudichZ, TanenbaumR. 1983. Evidence for a mechanical coupling of glycoprotein microfibrils with collagen fibrils in Wharton's jelly. Biochim Biophys Acta, 755:376–387.
33.
ShinKS, LeeHJ, JungJ, ChaDH, KimGJ. 2010. Culture and in vitro hepatogenic differentiation of placenta-derived stem cells, using placental extract as an alternative to serum. Cell Prolif, 43:435–444.
34.
De BruynC, NajarM, RaicevicG, MeulemanN, PietersK, StamatopoulosB, DelforgeA, BronD, LagneauxL. 2011. A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. Stem Cells Dev, 20:547–557.
BankowskiE, SobolewskiK, RomanowiczL, ChyczewskiL, JaworskiS. 1996. Collagen and glycosaminoglycans of Wharton's jelly and their alterations in EPH-gestosis. Eur J Obstet Gynecol Reprod Biol, 66:109–117.
37.
ReddyGK, EnwemekaCS. 1996. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem, 29:225–229.
38.
LiuS, YuanM, HouK, ZhangL, ZhengX, ZhaoB, SuiX, XuW, LuS, GuoQ. 2012. Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells. Cell Immunol, 278:35–44.
39.
KimBG, LiC, QiaoW, MamuraM, KasprzakB, AnverM, WolfraimL, HongS, MushinskiEet al.2006. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature, 441:1015–1019.
40.
LaemmliUK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227:680–685.
41.
TakeuchiY, SuzawaM, KikuchiT, NishidaE, FujitaT, MatsumotoT. 1997. Differentiation and transforming growth factor-beta receptor down-regulation by collagen-alpha2beta1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells. J Biol Chem, 272:29309–29316.
42.
MathewsS, BhondeR, GuptaPK, ToteyS. 2011. A novel tripolymer coating demonstrating the synergistic effect of chitosan, collagen type 1 and hyaluronic acid on osteogenic differentiation of human bone marrow derived mesenchymal stem cells. Biochem Biophys Res Commun, 414:270–276.
43.
LuLL, LiuYJ, YangSG, ZhaoQJ, WangX, GongW, HanZB, XuZS, LuYXet al.2006. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica, 91:1017–1026.
44.
RiekstinaU, CakstinaI, ParfejevsV, HoogduijnM, JankovskisG, MuiznieksI, MucenieceR, AncansJ. 2009. Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis. Stem Cell Rev, 5:378–386.
45.
BolstadBM, IrizarryRA, AstrandM, SpeedTP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics, 19:185–193.
46.
BosnakovskiD, MizunoM, KimG, TakagiS, OkumuraM, FujinagaT. 2005. Isolation and multilineage differentiation of bovine bone marrow mesenchymal stem cells. Cell Tissue Res, 319:243–253.
47.
CaloE, Quintero-EstadesJA, DanielianPS, NedelcuS, BermanSD, LeesJA. 2010. Rb regulates fate choice and lineage commitment in vivo. Nature, 466:1110–1114.
48.
IsmailAA, WagnerS, Murua EscobarH, WillenbrockS, SterenczakKA, SamyMT, Abd El-AalAM, NolteI, WefstaedtP. 2012. Effects of high-mobility group a protein application on canine adipose-derived mesenchymal stem cells in vitro. Vet Med Int, 2012:752083.
49.
ParkSB, SeoKW, SoAY, SeoMS, YuKR, KangSK, KangKS. 2012. SOX2 has a crucial role in the lineage determination and proliferation of mesenchymal stem cells through Dickkopf-1 and c-MYC. Cell Death Differ, 19:534–545.
50.
YuKR, YangSR, JungJW, KimH, KoK, HanDW, ParkSB, ChoiSW, KangSK, ScholerH, KangKS. 2012. CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells, 30:876–887.
51.
CaplanAI. 2009. Why are MSCs therapeutic? New data: new insight. J Pathol, 217:318–324.
52.
SantosF, AndradePZ, AbecasisMM, GimbleJM, ChaseLG, CampbellAM, BoucherS, VemuriMC, SilvaCL, CabralJM. 2011. Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods, 17:1201–1210.
53.
LiewA, O'BrienT. 2012. Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther, 3:28.
54.
MimuraS, KimuraN, HirataM, TateyamaD, HayashidaM, UmezawaA, KoharaA, NikawaH, OkamotoT, FurueMK. 2011. Growth factor-defined culture medium for human mesenchymal stem cells. Int J Dev Biol, 55:181–187.
55.
LinH, YangG, TanJ, TuanRS. 2012. Influence of decellularized matrix derived from human mesenchymal stem cells on their proliferation, migration and multi-lineage differentiation potential. Biomaterials, 33:4480–4489.
56.
SpeesJL, GregoryCA, SinghH, TuckerHA, PeisterA, LynchPJ, HsuSC, SmithJ, ProckopDJ. 2004. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther, 9:747–756.
57.
UngerC, SkottmanH, BlombergP, DilberMS, HovattaO. 2008. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet, 17:R48R53.
58.
Bocelli-TyndallC, ZajacP, Di MaggioN, TrellaE, BenvenutoF, IezziG, ScherberichA, BarberoA, SchaerenSet al.2010. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum, 62:3815–3825.
59.
ShahdadfarA, FronsdalK, HaugT, ReinholtFP, BrinchmannJE. 2005. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells, 23:1357–1366.
60.
AntoniouGA, AntoniouSA, DoddDP. 2012. Use of porcine dermal collagen implant for definite early closure of the open abdomen in aortic surgery. Int Angiol, 31:303–304.
61.
GhanaatiS. 2012. Non-cross-linked porcine-based collagen I-III membranes do not require high vascularization rates for their integration within the implantation bed: a paradigm shift. Acta Biomater, 8:3061–3072.
62.
VasioukhinV, BauerC, DegensteinL, WiseB, FuchsE. 2001. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell, 104:605–617.
63.
BennettWR, CrewTE, SlackJM, WardA. 2003. Structural-proliferative units and organ growth: effects of insulin-like growth factor 2 on the growth of colon and skin. Development, 130:1079–1088.
64.
MajackRA, CookSC, BornsteinP. 1986. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc Natl Acad Sci U S A, 83:9050–9054.
65.
LongMW, DixitVM. 1990. Thrombospondin functions as a cytoadhesion molecule for human hematopoietic progenitor cells. Blood, 75:2311–2318.
66.
KilianO, FleschI, WenischS, TaborskiB, JorkA, SchnettlerR, JonuleitT. 2004. Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. Eur J Med Res, 9:337–344.
67.
BrunnerD, FrankJ, ApplH, SchofflH, PfallerW, GstraunthalerG. 2010. Serum-free cell culture: the serum-free media interactive online database. ALTEX, 27:53–62.
JungJ, MoonN, AhnJY, OhEJ, KimM, ChoCS, ShinJC, OhIH. 2009. Mesenchymal stromal cells expanded in human allogenic cord blood serum display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev, 18:559–571.
70.
KocaoemerA, KernS, KluterH, BiebackK. 2007. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells, 25:1270–1278.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
